Psychiatric manifestations of autoimmune disorders

Current Treatment Options in Neurology

Volumn 7, Issue 5, 2005, Pages 413-417

  Weiss, David B ^a   Dyrud, Jarl ^b   House, Robert M ^b   Beresford, Thomas P ^b  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PREDNISONE; PSYCHOTROPIC AGENT; STEROID;

ADDISON DISEASE; ANXIETY DISORDER; AUTOIMMUNE DISEASE; BEHAVIOR MODIFICATION; COGNITIVE DEFECT; DELIRIUM; DEPRESSION; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DOCTOR PATIENT RELATION; DOSE RESPONSE; EXERCISE; HASHIMOTO DISEASE; HUMAN; MANIA; MENTAL DISEASE; MOOD DISORDER; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; POLYARTERITIS; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; SARCOIDOSIS; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TEMPORAL ARTERITIS;

EID: 29744444462     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-005-0033-z     Document Type: Review

References (35)

1. Ciccarelli O, Werring DJ, Barker GJ, et al.: A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging-evidence of Wallerian degeneration. J Neurol 2003, 250:287-292.
2. Miller DH, Barkhof F, Frank JA, et al.: Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002, 125:1676-1695.
3. Rieckmann P, Maurer M: Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis. Curr Opin Neurol 2002, 15:361-370.
4. Sadovnick AD, Remick RA, Allen J, et al.: Depression and multiple sclerosis. Neurology 1996, 46:628-632.
5. Patten SB, Beck CA, Williams JVA, et al.: Major depression in multiple sclerosis, a population-based perspective. Neurology 2003, 61:1524-1527.
6. Diaz-Olavarrieta C, Cummings JL, Velazques J, et al.: Neuropsychiatric manifestations of multiple sclerosis. J Neuropsychiatry Clin Neurosci 1999, 11:51-57.
7. Feinstein A: An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002, 59:674-678.
8. Pujol J, Bello J, Deus J, et al.: Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology 1997, 49:1105-1110.
9. Fassbender K, Schmidt R, Mossner R, et al.: Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis. Arch Neurol 1998, 55:66-72.
10. Feinstein A, Roy P, Lobaugh N, et al.: Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004, 62:586-590.
11. Benedict RHB, Weinstock-Guttman B, Fishman I, et al.: Prediction of neuropsychological impairment in multiple sclerosis. Arch Neurol 2004, 61:226-230.
12. Mohr D, Goodkin DE, Bacchetti P, et al.: Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology 2002, 55:55-61.
13. Amato MP, Ponziani G, Siracusa G, Sorbi S: Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001, 58:1602-1606.
14. Tan EM, Cohen AS, Fries JF, et al.: The 1982 revised criteria for the classification of systemic lupus erythematosis. Arthritis Rheumatism 1997, 40:1725.
15. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
16. Mok CC, Lau KS, Wong RWS: Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2001, 28:766-771.
17. Brey RL, Holliday SL, Saklad AR, et al.: Neuropsychiatric syndromes in lupus. Neurology 2002, 58:1214-1220.
18. Belin C, Moroni C, Caillat-Vigneron N, et al.: Central nervous system involvement in Sjogren's syndrome: evidence from neuropsychological testing and HMPAO-SPECT. Ann Med Intern 1999, 150:598-604.
19. Brito GN, Araujo GR, Papi JA: Neuropsychological, neuroimage and psychiatric aspects of primary Sjogren's syndrome. Arq Neuropsiquiatr 2002, 60:28-31.
20. Valtysdottir ST, Gudbjornsson B, Lindqvist U, et al.: Anxiety and depression in patients with primary Sjogren's syndrome. J Rheumatol 2000, 27:165-169.
21. Valtysdottir ST, Gudbjornsson B, Hallgren R, Hetta J: Psychological well-being in patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2000, 18:597-600.
22. Mauch E, Volk C, Kratzsch G, et al.: Neurological and neuropsychiatric dysfunction in primary Sjogren's syndrome. Acta Neurol Scand 1994, 89:31-35.
23. Inafuku T, Watanbe M, Takagi M, et al.: Giant cell arteritis with bilateral obstruction of the internal carotid artery - report of an autopsy case. Rinsho Shinkeigaku Clin Neurol 1998, 38:323-328.
24. Granel B, Gaudy C, Serratrice J, et al.: Psychological and behavioral disorders with good outcome in neurosarcoidosis. Rev Med Intern 2001, 22:183-188.
25. Chang B, Steimel J, Moller DR, et al.: Depression in sarcoidosis. Am J Resp Crit Care Med 2001, 163:329-334.
26. Wirnsberger RM, de Vries J, Breteler MH, et al.: Evaluation of quality of life in sarcoidosis patients. Resp Med 1998, 92:750-756.
27. Benrud-Larson LM, Haythornthwaite JA, Heinberg LJ, et al.: The impact of pain and symptoms of depression in scleroderma. Pain 2002, 95:267-275.
28. Roca RP, Wigley FM, White B: Depressive symptoms associated with scleroderma. Arthritis Rheum 1996, 39:1035-1040.
29. Angelopoulos NV, Drosos AA, Moutsopoulos HM: Psychiatric symptoms associated with scleroderma. Psychother Psychosom 2001, 70:145-150.
30. Cutolo M, Nobili F, Sulli A, et al.: Evidence of cerebral hypoperfusion in scleroderma patients. Rheumatology 2000, 39:1366-1373.
31. Zetting G, Asenbaum S, Fueger BJ, et al.: Increased prevalence of subclinical brain perfusion abnormalities in patients with autoimmune thyroiditis: evidence of Hashimoto's encephalitis? Clin Endocrinol 2003, 59:643-647.
32. Chong JY, Rowland LF, Utiger RD: Hashimoto encephalopathy: syndrome or myth? Arch Neurol 2003, 60:164-171.
33. Teuber I, Volz HP: Acute schizophreniform disorder in Hashimoto disease. Psychiatr Praxis 2003, 30(Suppl 2):S83-S84.
34. Lishman WA: Organic Psychiatary: The Psychological Consequences of Cerebral Disorder, Third Edition. Oxford: Blackwell Scientific Publications; 1997:709-714.
35. Paul RH, Cohen RA, Gilchrist JM: Ratings of subjective mental fatigue relate to cognitive performance in patients with myasthenia gravis. J Clin Neurosci 2002, 9:243-246.